Shire Re-petitions On Mesalamine, Says FDA Flunked Bibliography
This article was originally published in The Pink Sheet Daily
Executive Summary
Appeal of the agency's partial rejection of the company's citizen petition on standards for mesalamine ANDAs argues that FDA needs to provide more scientific backing for its decision to allow approval based on PK studies.
You may also be interested in...
FDA Reverses Stance On Bioequivalence Standards For Mesalamine
FDA believes that comparative pharmacokinetic studies, instead of comparative clinical endpoint studies, are best for determining bioequivalence of extended- or delayed-release mesalamine products - a reversal of its previous position
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.